Loading...
OTCM
TBPMQ
Market cap0USD
May 27, Last price  
0.00USD
Name

Tetra Bio Pharma Inc

Chart & Performance

D1W1MN
OTCM:TBPMQ chart
P/E
0.00
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
00000000000112,320000
Net income
-52m
L+97.06%
-134,183-1,685,886-373,455-509,868-1,456,215-554,909-2,109,399-414,130-594,780-944,257-6,225,294-7,572,555-15,282,933-26,476,177-52,175,046
CFO
-25m
L+28.72%
-117,556-487,607-213,627-431,126-1,447,681-284,614-143,551-233,116-216,722-942,331-3,892,013-9,505,228-17,343,299-19,636,172-25,276,074

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Headquartered in Orléans, Canada, Tetra Bio-Pharma Inc. is a biopharmaceutical company focused on discovering and developing cannabinoid-based medications. Their efforts span several therapeutic areas, including inflammation, pain management, ophthalmology, and oncology. The company's pipeline features various drug candidates: PLENITUDE is being developed for cancer-related pain in advanced patients, while REBORN addresses breakthrough cancer pain. Reduvo is designed to combat chemotherapy-induced nausea and vomiting. ARDS-003 targets sepsis and the prevention of acute respiratory distress syndrome, and SERENITY aims to treat cancer cachexia. Furthermore, Tetra Bio-Pharma is advancing PPP003 for painful dry eye and uveitis pain, and HCC011 for hepatocellular carcinoma.
IPO date
Apr 15, 2008
Employees
33
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2021‑112020‑112019‑112018‑112017‑112016‑11
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT